The application of preoperative neoadjuvant chemotherapy in patients with stageⅢA non-small cell lung cancer
10.3760/cma.j.issn.1008-1372.2017.12.024
- VernacularTitle:新辅助化疗在ⅢA期非小细胞肺癌术前应用临床分析
- Author:
Li XIA
1
;
Mina JIANG
;
Zhining WU
;
Wenxiang WANG
Author Information
1. 湖南省长沙市第八医院胸心外科
- Keywords:
Chemotherapy;
adjuvant;
Carcinoma;
non-small-cell lung/TH
- From:
Journal of Chinese Physician
2017;19(12):1844-1846
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical efficacy of neoadjuvant chemotherapy in patients with stageⅢA non-small cell lung cancer (NSCLC). Methods From March 2008 to October 2015, there were 92 cases of stageⅢA NSCLC patients received 2 cycles of neoadjuvant chemotherapy and underwent radical surgery for lung cancer 3-4 weeks late ( observation group) , and another group of 65 cases of stage ⅢA NSCLC patients ( control group) underwent surgery for lung cancer without preoperative chemotherapy. The clinical data as well as early and meddle term surgical outcome of both groups were analyzed retrospectively. Results The neoadjuvant chemotherapy effective rate was 73. 9％ in the observation group. All surgeries for lung cancer patients were undertaken either with video-assisted thoracotomy or traditional thoracotomy. No operative mortality and the postoperative pathology findings were in accordance with NSCLC. The bleed-ing amount and operation time of two groups were similar; the resection rate of the observation group was greater than that of the control group. All patients were followed up at least 3 years, and the 2 years and 3 years survival rate of the observation group was slightly higher than that of the control group. Conclusions Preoperative neoadjuvant chemotherapy in patients with NSCLC can improve the resection rate and prolong the survival time, which is worthy of clinical application.
